Nonetheless, our preclinical studies point toward the existence of a therapeutic window for safely and effectively targeting PTPN2 and/or PTP1B and enhancing anti-tumor immunity and the response to immunotherapy. The gene discussed is PTPN2; the disease is neoplasm.